News about Clinical Trials

Regenxbio Reports Positive Pivotal Trial Results for Duchenne Gene Therapy RGX-202

Regenxbio’s investigational gene therapy RGX-202 demonstrated strong microdystrophin expression, functional gains and a favourable safety profile in Duchenne muscular dystrophy patients, supporting plans for accelerated approval and a potential commercial launch in 2027.

Clinical Trials | 15/05/2026 | By News Bureau |  101

Biogen Announces Topline Phase 2 Results for Diranersen in Early Alzheimer's Disease

Ionis partner Biogen announces topline phase 2 CELIA trial results for diranersen (BIIB080), showing reduced tau pathology and cognitive benefits in patients with early Alzheimer's Disease (AD).

Clinical Trials | 15/05/2026 | By News Bureau |  137

AskBio Doses First Participant in Phase 1/2 Trial for Pompe Disease Gene Therapy

AskBio has dosed the first participant in its Phase 1/2 PROGRESS-GT LOPD trial evaluating investigational gene therapy AB-1009 for late-onset Pompe disease, advancing research into potential long-term treatment solutions for the rare genetic disorder.

Clinical Trials | 14/05/2026 | By News Bureau

Novo Nordisk Higher-Dose Wegovy Shows 28 Percent Weight Loss in Early Responders

Novo Nordisk reports new analyses showing higher-dose Wegovy helped early responders achieve up to 28 percent weight loss, highlighting its effectiveness for obesity treatment regardless of response speed.

Clinical Trials | 13/05/2026 | By News Bureau |  114

Eli Lilly's Foundayo and Lower-Dose Zepbound Maintain Weight Loss in Late-Phase Trials

Eli Lilly and Company reports late-stage trial data showing Foundayo and lower-dose Zepbound helped patients maintain significant long-term weight loss after switching from higher-dose incretin therapies.

Clinical Trials | 13/05/2026 | By News Bureau |  124

Ranok Therapeutics Reports Promising Phase 1a Results for KRAS G12D Cancer Therapy RNK08954

Ranok Therapeutics has reported positive Phase 1a clinical data for investigational KRAS G12D inhibitor RNK08954, demonstrating encouraging response rates and tolerability in advanced solid tumor patients, including those with non-small cell lung cancer.

Clinical Trials | 12/05/2026 | By News Bureau |  212

Hengrui Pharma and Braveheart Bio Report Positive Phase 2 Results for Cardiac Therapy HRS/BHB-1893 in nHCM

Hengrui Pharma and Braveheart Bio have reported positive Phase 2 clinical trial results for investigational cardiac therapy HRS/BHB-1893 in patients with non-obstructive hypertrophic cardiomyopathy, demonstrating improvements in cardiac function, biomarkers and patient outcomes.

Clinical Trials | 12/05/2026 | By News Bureau |  180

Mabwell Secures FDA Clearance for 9MW5211 Clinical Trial Application

Mabwell receives US Food and Drug Administration (FDA) IND clearance for 9MW5211, a novel antibody therapy being developed for Inflammatory Bowel Disease (IBD) clinical studies.

Clinical Trials | 11/05/2026 | By News Bureau |  110

Bayer Reports Positive Phase 3 Results for Investigational Cardiac Amyloidosis Imaging Agent

REVEAL study demonstrates strong diagnostic sensitivity and specificity of I 124 evuzamitide PET/CT radiotracer for detecting cardiac amyloidosis, supporting plans for regulatory discussions with the FDA.

Clinical Trials | 08/05/2026 | By News Bureau |  144

Samsung Bioepis achieves positive Phase 1 results for Keytruda biosimilar candidate SB27

The biopharmaceutical company announced that its proposed pembrolizumab biosimilar, SB27, met primary pharmacokinetic endpoints in a global Phase 1 study involving non-small cell lung cancer patients, advancing its oncology biosimilar pipeline.

Clinical Trials | 08/05/2026 | By News Bureau |  182